ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 4.080
+0.380 (10.27%)
Aug 27, 2026, 4:08 PM HKT
HKG:1541 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 141.69 | 154.29 | 74.15 | 0.39 | 0.54 | 5.07 |
Other Revenue | -15.69 | - | - | 7.31 | 5.15 | 8.74 |
| 126 | 154.29 | 74.15 | 7.7 | 5.69 | 13.81 | |
Revenue Growth | 2.58% | 108.09% | 863.60% | 35.24% | -58.79% | - |
Cost of Revenue | 1.11 | 1.11 | - | - | - | - |
Gross Profit | 124.89 | 153.18 | 74.15 | 7.7 | 5.69 | 13.81 |
Selling, General & Admin | 49.88 | 53.94 | 64.82 | 80.42 | 92.8 | 48.32 |
Research & Development | 309.01 | 322.28 | 322.76 | 291.94 | 277.35 | 175.95 |
Operating Expenses | 358.89 | 376.22 | 387.58 | 372.37 | 370.14 | 224.27 |
Operating Income | -234 | -223.04 | -313.43 | -364.67 | -364.45 | -210.47 |
Interest Expense | -7.09 | -5.3 | -3.45 | -1.52 | -0.79 | -0.89 |
Interest & Investment Income | 6.84 | 6.84 | 6.38 | 10.8 | 9.51 | 1.64 |
Currency Exchange Gain (Loss) | -7.62 | -7.62 | 1.79 | 0.1 | 26.11 | -9.13 |
Other Non Operating Income (Expenses) | 9.8 | 9.8 | 5.37 | -25.92 | -73.27 | -514.83 |
EBT Excluding Unusual Items | -232.07 | -219.32 | -303.34 | -381.22 | -402.89 | -733.67 |
Gain (Loss) on Sale of Investments | 0.06 | 0.06 | 14.15 | 1.76 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.56 |
Asset Writedown | - | - | -27.4 | - | - | - |
Other Unusual Items | - | - | - | - | - | 0.17 |
Pretax Income | -232.01 | -219.26 | -316.59 | -379.46 | -402.89 | -732.95 |
Income Tax Expense | 0.05 | 0.03 | - | - | - | - |
Earnings From Continuing Operations | -232.06 | -219.29 | -316.59 | -379.46 | -402.89 | -732.95 |
Minority Interest in Earnings | 1.88 | 0.71 | 0.74 | - | - | - |
Net Income | -230.18 | -218.58 | -315.86 | -379.46 | -402.89 | -732.95 |
Net Income to Common | -230.18 | -218.58 | -315.86 | -379.46 | -402.89 | -732.95 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 422 | 412 | 377 | 362 | 332 | 86 |
Shares Outstanding (Diluted) | 422 | 412 | 377 | 362 | 332 | 86 |
Shares Change | 7.25% | 9.35% | 4.24% | 9.05% | 284.99% | - |
EPS (Basic) | -0.55 | -0.53 | -0.84 | -1.05 | -1.21 | -8.50 |
EPS (Diluted) | -0.55 | -0.53 | -0.84 | -1.05 | -1.21 | -8.50 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -203.9 | -138.44 | -370.25 | -261.93 | -231.24 |
Free Cash Flow Per Share | - | -0.49 | -0.37 | -1.02 | -0.79 | -2.68 |
Gross Margin | 99.12% | 99.28% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -185.71% | -144.55% | -422.70% | -4739.09% | -6405.13% | -1524.23% |
Profit Margin | -182.68% | -141.66% | -425.97% | -4931.24% | -7080.74% | -5308.15% |
Free Cash Flow Margin | - | -132.15% | -186.70% | -4811.50% | -4603.41% | -1674.69% |
EBITDA | -225.76 | -214.71 | -303.15 | -352.26 | -352.54 | -202.69 |
EBITDA Margin | -179.17% | -139.16% | - | - | - | - |
D&A For EBITDA | 8.24 | 8.33 | 10.28 | 12.41 | 11.91 | 7.77 |
EBIT | -234 | -223.04 | -313.43 | -364.67 | -364.45 | -210.47 |
EBIT Margin | -185.71% | -144.55% | - | - | - | - |